Pathogenesis of adrenocortical cancer

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 2, 2009, Pages 261-271

  Bertherat, Jérôme ^a   Bertagna, Xavier ^a  

^a INSERM   (France)

Author keywords

catenin; adrenocortical cancer; IGF II; TP53; trancriptome

Indexed keywords

BETA CATENIN; CORTICOTROPIN RECEPTOR; PROTEIN P53; SOMATOMEDIN B; WNT PROTEIN;

ADRENAL CORTEX CARCINOMA; BECKWITH WIEDEMANN SYNDROME; CANCER DIAGNOSIS; CARCINOGENESIS; CHROMOSOME 11P; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME REARRANGEMENT; COLON POLYPOSIS; FAMILIAL CANCER; GENE EXPRESSION PROFILING; HETEROZYGOSITY LOSS; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; PROGNOSIS; REVIEW; SOMATIC MUTATION; TRANSCRIPTOMICS; TUMOR SUPPRESSOR GENE;

ADRENAL CORTEX NEOPLASMS; ADULT; ANIMALS; CLONE CELLS; GENE EXPRESSION PROFILING; HUMANS; MODELS, BIOLOGICAL;

EID: 66549090652     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.10.006     Document Type: Review

References (67)

1. Grumbach M.M., Biller B.M., Braunstein G.D., et al. Management of the clinically inapparent adrenal mass ('incidentaloma'). Annals of Internal Medicine 138 (2003) 424-429
2. Luton J.P., Cerdas S., Billaud L., et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. New England Journal of Medicine 322 (1990) 1195-1201
3. Allolio B., Hahner S., Weismann D., et al. Management of adrenocortical carcinoma. Clinical Endocrinology (Oxford) 60 (2004) 273-287
4. Abiven G., Coste J., Groussin L., et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. Journal of Clinical Endocrinology and Metabolism 91 (2006) 2650-2655
5. Libe R., Fratticci A., and Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocrine-Related Cancer 14 (2007) 13-28
6. Libe R., and Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. European Journal of Endocrinology 153 (2005) 477-487
7. Gicquel C., Leblond-Francillard M., Bertagna X., et al. Clonal analysis of human adrenocortical carcinomas and secreting adenomas. Clinical Endocrinology (Oxford) 40 (1994) 465-477
8. Beuschlein F., Reincke M., Karl M., et al. Clonal composition of human adrenocortical neoplasms. Cancer Research 54 (1994) 4927-4932
9. Sidhu S., Marsh D.J., Theodosopoulos G., et al. Comparative genomic hybridization analysis of adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 87 (2002) 3467-3474
10. Kjellman M., Kallioniemi O.P., Karhu R., et al. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Research 56 (1996) 4219-4223
11. Kjellman M., Roshani L., Teh B.T., et al. Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. Journal of Clinical Endocrinology and Metabolism 84 (1999) 730-735
12. Zhao J., Speel E.J., Muletta-Feurer S., et al. Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. American Journal of Pathology 155 (1999) 1039-1045
13. Dohna M., Reincke M., Mincheva A., et al. Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer 28 (2000) 145-152
14. Gicquel C., Bertagna X., Gaston V., et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Research 61 (2001) 6762-6767
15. Caron de Fromentel C., and Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 4 (1992) 1-15
16. Hisada M., Garber J.E., Fung C.Y., et al. Multiple primary cancers in families with Li-Fraumeni syndrome. Journal of the National Cancer Institute 90 (1998) 606-611
17. Bell D.W., Varley J.M., Szydlo T.E., et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286 (1999) 2528-2531
18. Wagner J., Portwine C., Rabin K., et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. Journal of the National Cancer Institute 86 (1994) 1707-1710
19. Varley J.M., McGown G., Thorncroft M., et al. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. American Journal of Human Genetics 65 (1999) 995-1006
20. Ribeiro R.C., Sandrini F., Figueiredo B., et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proceedings of the National Academy of Sciences of the United States of America 98 (2001) 9330-9335
21. Latronico A.C., Pinto E.M., Domenice S., et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 86 (2001) 4970-4973
22. DiGiammarino E.L., Lee A.S., Cadwell C., et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nature Structural Biology 9 (2002) 12-16
23. Ohgaki H., Kleihues P., and Heitz P.U. p53 mutations in sporadic adrenocortical tumors. International Journal of Cancer 54 (1993) 408-410
24. Reincke M., Karl M., Travis W.H., et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. Journal of Clinical Endocrinology and Metabolism 78 (1994) 790-794
25. Libe R., Groussin L., Tissier F., et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clinical Cancer Research 13 (2007) 844-850
26. Yano T., Linehan M., Anglard P., et al. Genetic changes in human adrenocortical carcinomas. Journal of the National Cancer Institute 81 (1989) 518-523
27. Soon P.S., Libe R., Benn D.E., et al. Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors. Annals of Surgery 247 (2008) 157-164
28. DeChiara T.M., Robertson E.J., and Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 64 (1991) 849-859
29. Hao Y., Crenshaw T., Moulton T., et al. Tumour-suppressor activity of H19 RNA. Nature 365 (1993) 764-767
30. Matsuoka S., Edwards M.C., Bai C., et al. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes & Development 9 (1995) 650-662
31. Lee M.H., Reynisdottir I., and Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes & Development 9 (1995) 639-649
32. Lam W.W., Hatada I., Ohishi S., et al. Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. Journal of Medical Genetics 36 (1999) 518-523
33. Wiedemann H.R., Burgio G.R., Aldenhoff P., et al. The proteus syndrome. Partial gigantism of the hands and/or feet, nevi, hemihypertrophy, subcutaneous tumors, macrocephaly or other skull anomalies and possible accelerated growth and visceral affections. European Journal of Pediatrics 140 (1983) 5-12
34. Hertel N.T., Carlsen N., Kerndrup G., et al. Late relapse of adrenocortical carcinoma in Beckwith-Wiedemann syndrome. Clinical, endocrinological and genetic aspects. Acta Paediatrica 92 (2003) 439-443
35. Mesiano S., Mellon S.H., and Jaffe R.B. Mitogenic action, regulation, and localization of insulin-like growth factors in the human fetal adrenal gland. Journal of Clinical Endocrinology and Metabolism 76 (1993) 968-976
36. Gicquel C., Bertagna X., Schneid H., et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 78 (1994) 1444-1453
37. Ilvesmaki V., Kahri A.I., Miettinen P.J., et al. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. Journal of Clinical Endocrinology and Metabolism 77 (1993) 852-858
38. Boulle N., Logie A., Gicquel C., et al. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 83 (1998) 1713-1720
39. Gicquel C., Raffin-Sanson M.L., Gaston V., et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. Journal of Clinical Endocrinology and Metabolism 82 (1997) 2559-2565
40. Giordano T.J., Thomas D.G., Kuick R., et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. American Journal of Pathology 162 (2003) 521-531
41. de Fraipont F., El Atifi M., Cherradi N., et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. Journal of Clinical Endocrinology and Metabolism 90 (2005) 1819-1829
42. Ogawa O., Eccles M.R., Szeto J., et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362 (1993) 749-751
43. Rainier S., Johnson L.A., Dobry C.J., et al. Relaxation of imprinted genes in human cancer. Nature 362 (1993) 747-749
44. Weber M.M., Auernhammer C.J., Kiess W., et al. Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. European Journal of Endocrinology 136 (1997) 296-303
45. Logie A., Boulle N., Gaston V., et al. Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. Journal of Molecular Endocrinology 23 (1999) 23-32
46. Boulle N., Baudin E., Gicquel C., et al. Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumors. European Journal of Endocrinology 144 (2001) 29-36
47. Gao Z.H., Suppola S., Liu J., et al. Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 87 (2002) 1170-1176
48. Liu J., Kahri A.I., Heikkila P., et al. Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-like growth factor II, and H19, in adrenal tumors and cultured adrenal cells. Journal of Clinical Endocrinology and Metabolism 82 (1997) 1766-1771
49. Kim A.C., Reuter A.L., Zubair M., et al. Targeted disruption of {beta}-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development 135 (2008) 2593-2602
50. Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Science 94 (2003) 225-229
51. Naylor E.W., and Gardner E.J. Adrenal adenomas in a patient with Gardner's syndrome. Clinical Genetics 20 (1981) 67-73
52. Blaker H., Sutter C., Kadmon M., et al. Analysis of somatic APC mutations in rare extracolonic tumors of patients with familial adenomatous polyposis coli. Genes Chromosomes Cancer 41 (2004) 93-98
53. Tissier F., Cavard C., Groussin L., et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Research 65 (2005) 7622-7627
54. Tadjine M., Lampron A., Ouadi L., et al. Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clinical Endocrinology (Oxford) 68 (2008) 264-270
55. S. Gaujoux, F. Tissier, L. Groussin, et al. Wnt/beta-catenin and cAMP/PKA signaling pathways alterations and somatic ss-catenin gene mutations in the progression of adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 2008; 93: 4135-4140.
56. M. Tadjine, A. Lampron, L. Ouadi, et al. Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease. Clinical Endocrinology (Oxford) 2008; 69: 367-373.
57. M. Doghman, J. Cazareth and E. Lalli. The Tcf/{beta}-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. Journal of Clinical Endocrinology and Metabolism 2008; 93: 3222-3225.
58. Thakker R.V. Multiple endocrine neoplasia-syndromes of the twentieth century. Journal of Clinical Endocrinology and Metabolism 83 (1998) 2617-2620
59. Schulte K.M., Mengel M., Heinze M., et al. Complete sequencing and messenger ribonucleic acid expression analysis of the MEN I gene in adrenal cancer. Journal of Clinical Endocrinology and Metabolism 85 (2000) 441-448
60. Heppner C., Reincke M., Agarwal S.K., et al. MEN1 gene analysis in sporadic adrenocortical neoplasms. Journal of Clinical Endocrinology and Metabolism 84 (1999) 216-219
61. Reincke M., Mora P., Beuschlein F., et al. Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. Journal of Clinical Endocrinology and Metabolism 82 (1997) 3054-3058
62. Reincke M., Beuschlein F., Lalli E., et al. DAX-1 expression in human adrenocortical neoplasms: implications for steroidogenesis. Journal of Clinical Endocrinology and Metabolism 83 (1998) 2597-2600
63. Fassnacht M., Beuschlein F., Vay S., et al. Aminoglutethimide suppresses adrenocorticotropin receptor expression in the NCI-h295 adrenocortical tumor cell line. Journal of Endocrinology 159 (1998) 35-42
64. Igaz P., Wiener Z., Szabo P., et al. Functional genomics approaches for the study of sporadic adrenal tumor pathogenesis: clinical implications. Journal of Steroid Biochemistry and Molecular Biology 101 (2006) 87-96
65. Velazquez-Fernandez D., Laurell C., Geli J., et al. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 138 (2005) 1087-1094
66. Slater E.P., Diehl S.M., Langer P., et al. Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. European Journal of Endocrinology 154 (2006) 587-598
67. Weiss L.M., Medeiros L.J., and Vickery Jr. A.L. Pathologic features of prognostic significance in adrenocortical carcinoma. American Journal of Surgical Pathology 13 (1989) 202-206